234 related articles for article (PubMed ID: 18094427)
21. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.
Zeng ZL; Luo HY; Yang J; Wu WJ; Chen DL; Huang P; Xu RH
Clin Cancer Res; 2014 Feb; 20(4):1042-52. PubMed ID: 24277452
[TBL] [Abstract][Full Text] [Related]
23. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
[TBL] [Abstract][Full Text] [Related]
26. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro.
Toulany M; Dittmann K; Fehrenbacher B; Schaller M; Baumann M; Rodemann HP
DNA Repair (Amst); 2008 Oct; 7(10):1746-56. PubMed ID: 18678286
[TBL] [Abstract][Full Text] [Related]
27. [Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].
Tegze B; Tulassay Z; Gyôrffy B
Magy Onkol; 2006; 50(4):315-23. PubMed ID: 17216005
[TBL] [Abstract][Full Text] [Related]
28. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
[TBL] [Abstract][Full Text] [Related]
29. A review of excision repair cross-complementation group 1 in colorectal cancer.
Bohanes P; Labonte MJ; Lenz HJ
Clin Colorectal Cancer; 2011 Sep; 10(3):157-64. PubMed ID: 21855036
[TBL] [Abstract][Full Text] [Related]
30. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
Rosa R; Marciano R; Malapelle U; Formisano L; Nappi L; D'Amato C; D'Amato V; Damiano V; Marfè G; Del Vecchio S; Zannetti A; Greco A; De Stefano A; Carlomagno C; Veneziani BM; Troncone G; De Placido S; Bianco R
Clin Cancer Res; 2013 Jan; 19(1):138-47. PubMed ID: 23166225
[TBL] [Abstract][Full Text] [Related]
31. Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo.
Kobunai T; Watanabe T; Fukusato T
Anticancer Res; 2011 Nov; 31(11):3691-6. PubMed ID: 22110188
[TBL] [Abstract][Full Text] [Related]
32. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.
Black PC; Brown GA; Dinney CP; Kassouf W; Inamoto T; Arora A; Gallagher D; Munsell MF; Bar-Eli M; McConkey DJ; Adam L
J Urol; 2011 Feb; 185(2):693-700. PubMed ID: 21168861
[TBL] [Abstract][Full Text] [Related]
33. Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines.
Luo HY; Wei W; Shi YX; Chen XQ; Li YH; Wang F; Qiu MZ; Li FH; Yan SL; Zeng MS; Huang P; Xu RH
Oncol Rep; 2010 Jun; 23(6):1735-45. PubMed ID: 20428833
[TBL] [Abstract][Full Text] [Related]
34. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma.
Prichard CN; Kim S; Yazici YD; Doan DD; Jasser SA; Mandal M; Myers JN
Laryngoscope; 2007 Apr; 117(4):674-9. PubMed ID: 17429874
[TBL] [Abstract][Full Text] [Related]
35. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
Bellone S; Frera G; Landolfi G; Romani C; Bandiera E; Tognon G; Roman JJ; Burnett AF; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Sep; 106(3):513-20. PubMed ID: 17540437
[TBL] [Abstract][Full Text] [Related]
37. Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin.
Narvi E; Vaparanta K; Karrila A; Chakroborty D; Knuutila S; Pulliainen A; Sundvall M; Elenius K
Sci Rep; 2018 Nov; 8(1):16579. PubMed ID: 30410004
[TBL] [Abstract][Full Text] [Related]
38. PTEN status in advanced colorectal cancer treated with cetuximab.
Negri FV; Bozzetti C; Lagrasta CA; Crafa P; Bonasoni MP; Camisa R; Pedrazzi G; Ardizzoni A
Br J Cancer; 2010 Jan; 102(1):162-4. PubMed ID: 19953097
[TBL] [Abstract][Full Text] [Related]
39. Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.
Giordano G; Febbraro A; Tomaselli E; Sarnicola ML; Parcesepe P; Parente D; Forte N; Fabozzi A; Remo A; Bonetti A; Manfrin E; Ghasemi S; Ceccarelli M; Cerulo L; Bazzoni F; Pancione M
J Exp Clin Cancer Res; 2015 Oct; 34():108. PubMed ID: 26427914
[TBL] [Abstract][Full Text] [Related]
40. Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.
Santoro V; Jia R; Thompson H; Nijhuis A; Jeffery R; Kiakos K; Silver AR; Hartley JA; Hochhauser D
J Natl Cancer Inst; 2016 Jun; 108(6):djv394. PubMed ID: 26719345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]